NCT01506154已完成3 期
A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of MRX-7EAT Topical Patch in the Treatment of Pain Due to Recent Onset Supraspinatous and/or Subacromial Tendonitis/Bursitis and/or Subdeltoid Bursitis of Shoulder
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 210
- 主要终点
- Mean of all 16 Current Pain Intensity scores collected on Days 4 through 7 on a 0-10 NPRS.
研究概览
简要总结
A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Pain due to Recent Onset Supraspinatous and/or Subacromial Tendonitis/Bursitis and/or Subdeltoid Bursitis of the Shoulder.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 14 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Females of child bearing potential must have a negative pregnancy test and be using an adequate method of birth control.
- •Subject has a diagnosis of acute supraspinatous or subacromial bursitis/tendonitis and/or subdeltoid bursitis of one shoulder with the onset of the current episode ≥ 24 hours and ≤ 7 days preceding the screening visit.
- •Subject has a Current Pain Intensity rated prior to study entry ≥ 6 but ≤ 8 on a Numeric Pain Rating Scale (NPRS).
排除标准
- •Subject has a suspected tear in the rotator cuff, calcific tendonitis, adhesive capsulitis, shoulder fractures, bilateral shoulder pain, bilateral tendonitis and/or bursitis of the shoulders, bicipital tendonitis; or orthopedic surgical treatment is required.
- •Subject has a positive Drop Arm Test indicative of a suspected tear; a positive O'Brien's Test suggestive of a glenoid labral tear; a positive Apprehension Test which would be indicative of glenohumeral instability; a positive Yergason's Test which would be indicative of bicipital tendonitis.
- •Subject had a previous episode of shoulder pain in the same area within two weeks prior to the current episode; history of chronic pain in the target shoulder; history of rotator cuff injury or previous surgery in the same area.
- •Subject received passive physical therapy treatments for the pain in the target shoulder within the past 24 hours.
- •Subject has used oral pharmacologic treatment less than 5 half-lives before the baseline assessments.
- •Subject has used any form of opioid within 24 hours of study entry or use of opioids for 5 or more consecutive days within the 30 days preceding enrollment.
- •Subject has received systemic corticosteroids in the 30 days preceding the screening visit; or local injections such as intra-articular, bursal, peritendinous; topical corticosteroids are acceptable unless applied to the target joint; and inhaled or intranasal steroids acceptable (e.g., Flonase®).
- •Subject recently initiated sleep medications, muscle relaxants, anticonvulsants or antidepressants (within the past 30 days).
- •Subject used TNF alpha blockers or Class 1 anti-arrhythmic drugs within the past 60 days.
- •Subject has a history or physical assessment finding of clinically significant GI ulcers or abnormal bleeding, anemia, kidney disease, liver disease, poorly controlled lung, stomach, heart, or other vital organ disease as determined by the study investigator/physician.
- •Subject has fibromyalgia, spondyloarthropathies (SpA) or other systemic arthritis such as rheumatoid arthritis. Arthritis typically localized such as gout or osteoarthritis is acceptable as long as it does not affect the injured area.
- •Subject has a painful syndrome (e.g. sciatica) or cervical spine disorder leading to a nerve entrapment syndrome or other medical problem that in the investigator's opinion may interfere with pain measurement of the target joint.
- •Subject has active skin lesions or disease at the intended site of study medication application, which may be covered by the patch. Skin lesions include open wounds, rash, papules and vesicles; abrasions, lacerations or any break in skin.
- •Subject has a history of allergy to etodolac, other NSAIDs, lidocaine or adhesives (e.g., adhesive tape).
- •Subject is scheduled for elective surgery or other invasive procedures during the period of study participation.
研究组 & 干预措施
Placebo
Placebo Comparator
Therapy with placebo
干预措施: MRX-7EAT (Drug)
MRX-7EAT
Experimental
Therapy with experimental drug
干预措施: MRX-7EAT (Drug)
结局指标
主要结局
Mean of all 16 Current Pain Intensity scores collected on Days 4 through 7 on a 0-10 NPRS.
时间窗: 7 days
次要结局
未报告次要终点
研究者
相似试验
已完成
3 期
MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Tendonitis and Bursitis of the ShoulderAcute TendonitisBursitisNCT01161615MEDRx USA, Inc.350
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and DapagliflozinType2 DiabetesNCT04885712Boryung Pharmaceutical Co., Ltd378
进行中（未招募）
3 期
A Study of Efficacy and Safety of TLL-018 in CSU ParticipantsChronic Spontaneous UrticariaNCT06396026Hangzhou Highlightll Pharmaceutical Co., Ltd440
终止
3 期
Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 InfectionSARS-CoV-2 InfectionNCT05109611Sanotize Research and Development corp.1,389
已完成
3 期
Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart FailureChronic Systolic Heart FailureNCT04468529Zensun Sci. & Tech. Co., Ltd.154